Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms

Terra Lasho, PhD, Alexander Tischer, PhD, Guadalupe Belen Antelo, MD, Animesh Pardanani, MBBS, PhD, Christy Finke, BS, Giacomo Coltro, MD, Wilson I Gonsalves, MD, Ayalew Tefferi, MD, Abhishek A Mangaonkar, MBBS, Naseema Gangat, MBBS, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 1697.

https://doi.org/10.1182/blood-2019-128067

Published: 2019

Journal Articles

Signaling Pathways of Mutant IDH1 Independent of R-2-Hydroxyglutarate

Charu Gupta, Michelle Maria Araujo Cruz, PhD, Nidhi Jyotsana, PhD, Amit Sharma, PhD, Ramya Goparaju, PhD, Kerstin Görlich, Renate Schottmann, Eduard Struys, PhD, Erwin E Jansen, Felicitas Thol, MD, Arnold Ganser, MD, Michael Heuser, MD, Anuhar Chaturvedi, PhD

Blood (2018) 132 (Supplement 1): 2617.

https://doi.org/10.1182/blood-2018-99-110159

Published: 2018

Journal Articles

Isoprenoid Amide Bisphosphonates As a Novel Class of Geranylgeranyl Diphosphate Synthase Inhibitors

Michelle L. Varney, MS, Daniel B. Goetz, BA, David F. Wiemer, PhD, Sarah A. Holstein, MD PhD

Blood (2018) 132 (Supplement 1): 4679.

https://doi.org/10.1182/blood-2018-99-112965

Published: 2018

Journal Articles

The ETS Inhibitors Yk-4-279 and TK-216 Interfere with Spib and Synergize with Lenalidomide in Diffuse Large B Cell Lymphoma of the Activated B Cell-like Type (ABC DLBCL)

Elaine Y Chung, PhD, Filippo Spriano, Ivo Kwee, PhD, Sara Napoli, Chiara Tarantelli, PhD, Eugenio Gaudio, PhD, Luciano Cascione, PhD, Andrea Cavalli, Alberto Arribas, PhD, Andrea Rinaldi, Davide Rossi, MD PhD, Emanuele Zucca, MD, Anastasios Stathis, MD, Katti Jessen, PhD, Brian J Lannutti, PhD, Jeffrey Toretsky, MD, Francesco Bertoni, MD

Blood (2017) 130 (Supplement 1): 2810.

https://doi.org/10.1182/blood.V130.Suppl_1.2810.2810

Published: 2017

Journal Articles

Mitochondrial Metabolism and RNA Methylation in DLBCL

Sara Elkashef, PhD, An-Ping Lin, MD, Lilly Chiou, Jamie Myers, MSc, ZhiJun Qiu, PhD, Ricardo C.T. Aguiar, MD PhD

Blood (2017) 130 (Supplement 1): 2732.

https://doi.org/10.1182/blood.V130.Suppl_1.2732.2732

Published: 2017

Journal Articles

Gls Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth When Combined with 5-Azacitidine

Tianyu Cai, PhD, Philip L Lorenzi, PhD, Dinesh Rakheja, MD, Michael A Pontikos, Alessia Lodi, Lina Han, MD PhD, Qi Zhang, MD PhD, Helen Ma, MS, Mohamed Rahmani, PhD, Tushar Damodar Bhagat, PhD, Thomas D Horvath, PhD, Courtney D. DiNardo, MD MSCE, Steven Grant, MD, Stefano Tiziani, PhD, Amit Verma, MD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 4064.

https://doi.org/10.1182/blood.V128.22.4064.4064

Published: 2016

Journal Articles

Superior Activity of BET Protein Bromodomain Antagonist-Based Combination with JAK Kinase, PIM Kinase or Heat Shock Protein 90 Inhibitor Against Post-MPN-MF sAML Cells

Dyana T Saenz, Warren Fiskus, PhD, Taghi Manshouri, PhD, Baohua Sun, MD PhD, Stephanie Krieger, Simrit Parmar, MD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2015) 126 (23): 1269.

https://doi.org/10.1182/blood.V126.23.1269.1269

Published: 2015

Journal Articles

Role of Glutamine in Metabolic and Epigenetic Reprogramming in AML

Juliana Vélez Luján, PhDCandidate, Niki Zacharias, PhD, Dinesh Rakheja, MD, Tushar D Bhagat, PhD, Jaehyuk Lee, PhD, Prasanta Dutta, PhD, Doriann Gonzalez, MDStudent, Michael Andreeff, MD PhD, Pratip K Bhattacharya, PhD, Amit Verma, M.B.,B.S., Marina Konopleva, MD PhD

Blood (2015) 126 (23): 2559.

https://doi.org/10.1182/blood.V126.23.2559.2559

Published: 2015

Journal Articles

The Metabolite R-2-Hydroxyglutarate (R2HG) Collaborates with HoxA9 to Induce Monocytic Leukemia

Anuhar Chaturvedi, PhD, Michelle Maria Araujo Cruz, Nidhi Jyotsana, Amit Sharma, PhD, Ramya Goparaju, Vishwas Sharma, PhD, Adrian Schwarzer, MDPhD, Kerstin Goerlich, Renate Schottmann, Eduard A. Struys, PhD, Erwin E. Jansen, Robert Geffers, PhD, Gudrun Goehring, MD, Felicitas Thol, MD, Arnold Ganser, Michael Heuser, MD

Blood (2014) 124 (21): 366.

https://doi.org/10.1182/blood.V124.21.366.366

Published: 2014

Journal Articles

IDH Mutations, 2-Oxoglutarate-dependent Dioxygenases, and Leukemia

William G. Kaelin, MD

Blood (2014) 124 (21): SCI-6.

https://doi.org/10.1182/blood.V124.21.SCI-6.SCI-6

Published: 2014

Journal Articles

Leukemia-Associated Oncometabolite 2-Hydroxyglutarate Regulates Epigenetic Modifications in Response to Oxygen Availability in Cells without IDH1/2 Mutations

Andrew M. Intlekofer, MD PhD, Raymond G. Dematteo, BS, Lydia W. Finley, PhD, Justin R. Cross, PhD, Craig B. Thompson, MD

Blood (2014) 124 (21): 872.

https://doi.org/10.1182/blood.V124.21.872.872

Published: 2014

Journal Articles

Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells

John A Valenta, M.S., Warren Fiskus, Ph.D, Taghi Manshouri, Ph.D., Sunil Sharma, MD, Jun Qi, PhD, Leasha J Schaub, M.S., Bhavin Shah, Melissa Rodriguez, M.D., Ph.D, Santhana Devaraj, Ph.D, Swaminathan Padmanabhan Iyer, MD, Srdan Verstovsek, MD, PhD, James E Bradner, MD, Kapil N. Bhalla, MD

Blood (2013) 122 (21): 2842.

https://doi.org/10.1182/blood.V122.21.2842.2842

Published: 2013

Journal Articles

Disruption Of Super Enhancer-Driven Cancer Dependencies In Diffuse Large B-Cell Lymphoma

Bjoern Chapuy, MD, PhD, McKeown Michael, Charles Y. Lin, PhD, Stefano Monti, PhD, Margaretha GM Roemer, Jun Qi, Peter B. Rahl, PhD, Heather Sun, Kelly T. Yeda, Andrew L. Kung, MD, PhD, Scott J. Rodig, MD, PhD, Richard A. Young, PhD, Margaret A. Shipp, MD, James E. Bradner, MD

Blood (2013) 122 (21): 3021.

https://doi.org/10.1182/blood.V122.21.3021.3021

Published: 2013

Journal Articles

Combined Therapy With BRD4 Antagonist and FLT3 Inhibitor Exerts Synergistic Activity Against Cultured and Primary AML Blast Progenitors Expressing FLT-ITD

Melissa Rodriguez, M.D., Ph.D, Warren Fiskus, Ph.D, Sunil Sharma, MD, Jun Qi, PhD, John A Valenta, M.S., Leasha J Schaub, M.S., Bhavin Shah, Santhana Devaraj, Ph.D, Swaminathan Padmanabhan Iyer, MD, James E Bradner, MD, Kapil N. Bhalla, MD

Blood (2013) 122 (21): 3821.

https://doi.org/10.1182/blood.V122.21.3821.3821

Published: 2013

Journal Articles

BRD4 Antagonist and Histone Deacetylase Inhibitor: A Novel Synergistic Combination Against Human Acute Myeloid Leukemia (AML) Cells

Warren Fiskus, Ph.D, Sunil Sharma, MD, Jun Qi, PhD, John A Valenta, M.S., Leasha J Schaub, M.S., Bhavin Shah, Karissa Peth, Laxmi U.M.R. Jakkula, PhD, Melissa Rodriguez, M.D., Ph.D, Santhana Devaraj, Ph.D, Swaminathan Padmanabhan Iyer, MD, James E Bradner, MD, Kapil N. Bhalla, MD

Blood (2013) 122 (21): 485.

https://doi.org/10.1182/blood.V122.21.485.485

Published: 2013

Journal Articles

Targeting IDH: the next big thing in AML

Mark Levis

Blood (2013) 122 (16): 2770–2771.

https://doi.org/10.1182/blood-2013-09-522441

Published: 2013

Journal Articles

The Small Molecule Inhibitor of VLA4 TBC3486 Sensitizes Resistant ALL to Chemotherapy

Yao-Te Hsieh, Eun Ji Gang, MD, PhD, Halvard Bonig, MD, MA, Ronald J Biediger, PhD, Peter Vanderslice, PhD, Yong-Mi Kim, MD, MPH, PhD

Blood (2012) 120 (21): 1500.

https://doi.org/10.1182/blood.V120.21.1500.1500

Published: 2012

Journal Articles

Transformation by Mutant IDH and ( R )-2HG Is Reversible.

Julie-Aurore Losman, MD, PhD, Ryan E. Looper, PhD, William G. Kaelin, Jr., MD

Blood (2012) 120 (21): 2413.

https://doi.org/10.1182/blood.V120.21.2413.2413

Published: 2012

Journal Articles

CTP-221, a Deuterated S -Enantiomer of Lenalidomide, Possesses Significantly Enhanced Immunomodulatory and Anti-Proliferative Properties Relative to the R -Enantiomer and to Racemic Lenalidomide.

Lijun Wu, Ph.D., Ara M. Aslanian, Ph.D., Julie F. Liu, Ph.D., Kristine Hogan, Roger Tung, Ph.D.

Blood (2012) 120 (21): 2463.

https://doi.org/10.1182/blood.V120.21.2463.2463

Published: 2012

Journal Articles

Mutated IDH1 Has 2-Hydroxyglutarate-Independent Functions in Leukemogenesis

Blood (2012) 120 (21): 770.

https://doi.org/10.1182/blood.V120.21.770.770

Published: 2012

NARROW

Functional Interrogation of Variants of Undetermined Significance of the Isocitrate Dehydrogenase 1 and 2 Genes in Myeloid Neoplasms

Signaling Pathways of Mutant IDH1 Independent of R-2-Hydroxyglutarate

Isoprenoid Amide Bisphosphonates As a Novel Class of Geranylgeranyl Diphosphate Synthase Inhibitors

The ETS Inhibitors Yk-4-279 and TK-216 Interfere with Spib and Synergize with Lenalidomide in Diffuse Large B Cell Lymphoma of the Activated B Cell-like Type (ABC DLBCL)

Mitochondrial Metabolism and RNA Methylation in DLBCL

Gls Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth When Combined with 5-Azacitidine

Superior Activity of BET Protein Bromodomain Antagonist-Based Combination with JAK Kinase, PIM Kinase or Heat Shock Protein 90 Inhibitor Against Post-MPN-MF sAML Cells

Role of Glutamine in Metabolic and Epigenetic Reprogramming in AML

The Metabolite R-2-Hydroxyglutarate (R2HG) Collaborates with HoxA9 to Induce Monocytic Leukemia

IDH Mutations, 2-Oxoglutarate-dependent Dioxygenases, and Leukemia

Leukemia-Associated Oncometabolite 2-Hydroxyglutarate Regulates Epigenetic Modifications in Response to Oxygen Availability in Cells without IDH1/2 Mutations

Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells

Disruption Of Super Enhancer-Driven Cancer Dependencies In Diffuse Large B-Cell Lymphoma

Combined Therapy With BRD4 Antagonist and FLT3 Inhibitor Exerts Synergistic Activity Against Cultured and Primary AML Blast Progenitors Expressing FLT-ITD

BRD4 Antagonist and Histone Deacetylase Inhibitor: A Novel Synergistic Combination Against Human Acute Myeloid Leukemia (AML) Cells

Targeting IDH: the next big thing in AML

The Small Molecule Inhibitor of VLA4 TBC3486 Sensitizes Resistant ALL to Chemotherapy

Transformation by Mutant IDH and ( R )-2HG Is Reversible.

CTP-221, a Deuterated S -Enantiomer of Lenalidomide, Possesses Significantly Enhanced Immunomodulatory and Anti-Proliferative Properties Relative to the R -Enantiomer and to Racemic Lenalidomide.

Mutated IDH1 Has 2-Hydroxyglutarate-Independent Functions in Leukemogenesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only